SCHEMBL6545200

SCHEMBL6545200

CC=COP(=O)(O)c1ccc(OC)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
TP53 P04637 2/20 0.41
LMNA P02545 1/20 0.41
CYP3A4 P08684 1/20 0.41
TSHR P16473 1/20 0.41
KDM4E B2RXH2 1/20 0.41
ACP3 P15309 1/20 0.41
CA1 P00915 6/20 0.39
CA2 P00918 6/20 0.39
CA12 O43570 2/20 0.39
CA9 Q16790 2/20 0.39
CA14 Q9ULX7 2/20 0.39
CA7 P43166 1/20 0.39
CYP2A6 P11509 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
PLK1 P53350 1/20 0.38
MMP2 P08253 1/20 0.37
F3 P13726 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3888849 0.84 LMNA (0.50) ALDH1A1LMNACYP3A4TSHRKDM4E
SCHEMBL779342 0.81 CA2 (0.45) ALDH1A1TSHRCA1CA2CA12
SCHEMBL18417833 0.79 CA1 (0.48) TP53ACP3CA1CA2CA12
SCHEMBL1618715 0.77 CA1 (0.49) TP53LMNAACP3CA1CA2
SCHEMBL226112 0.74 LMNA (0.56) TP53LMNATSHRACP3CA1
SCHEMBL233806 0.74 CA2 (0.52) TP53ACP3CA1CA2CA12
SCHEMBL16868490 0.73 MMP9 (0.47) ALDH1A1KDM4EACP3CA1CA2
SCHEMBL15304566 0.73 ACP3 (0.42) TP53ACP3CA1CA2CA12
SCHEMBL18417835 0.72 CA1 (0.50) ALDH1A1TP53ACP3CA1CA2
Hydrochloric Acid SCHEMBL5561013 0.72 CA2 (0.50) ALDH1A1TP53CYP3A4ACP3CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379533-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS Leo Pharma A/S (DK) 2004-01-14 EP disclosed
US-6605742-B2 Rheumatic diseases; antiarthritic agents; antitumor agents LEO PHARMA A/S (DK) 2003-08-12 US disclosed
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons LEO PHARMA A/S (DK) 2002-11-28 US disclosed
WO-2002083696-A2 NOVEL CYCLO AZAPHOSPHA HYDROCARBONS LEO PHARMA A/S (DK) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020177706-A1 Novel cyclo azaphospha hydrocarbons CMA1, MMP9, CPA1 ALDH1A1 1152/4885TP53 3227/4885LMNA 3479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.